EZN-2968 is a LNA directed against HIF1α that has shown great inhibition of HIF1α and HIF1α-dependent genes and that is currently under phase I clinical study because of its ability to reduce tumor growth in xenografts (Greenberger et al., 2008). The gene discussed is HIF1A; the disease is neoplasm.